organization · Reporting owner
Innovative Cellular Therapeutics Holdings Ltd
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | 10% owner | July 27, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date July 27, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,774,980 |
Reported balance
After 2026-07-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-27 · Other · Disposed 44,000 · Balance 2,774,980 F1: Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J. F2: Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
F2: Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 28, 2026 01:14 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | OtherCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029817 · form4.xml · nonDerivative · entry 1 Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,774,980 F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J. F2 · balance_after: Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred. Read SEC document |
| July 27, 2026 Filed Jul 27, 2026 23:59 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | OtherCommon Stock | 38,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029791 · form4.xml · nonDerivative · entry 1 Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,818,980 F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J. F2 · balance_after: Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 18:55 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 10 | $13.70 | $137.00 |
DisclosureSEC source: 0001140361-26-028955 · form4.xml · nonDerivative · entry 1 Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,857,480 F1 · balance_after: Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:45 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 10 | $13.73 | $137.30 |
DisclosureSEC source: 0001140361-26-028846 · form4.xml · nonDerivative · entry 1 Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,857,490 F1 · balance_after: Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 16:37 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | OtherCommon Stock | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-027140 · form4.xml · nonDerivative · entry 1 Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,857,500 F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J. F2 · balance_after: Reflects 2,933,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 76,000 shares transferred. Read SEC document |
| June 15, 2026 Filed Jun 19, 2026 01:59 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | OtherCommon Stock | 66,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-025796 · form4.xml · nonDerivative · entry 1 Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,933,500 F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J. F2 · balance_after: Reflects 3,000,000 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 66,500 shares transferred. All shares are held directly and registered in the name of the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.